Dolutegravir Superior in Women-Only Study

On behalf of IFARA, Fred Schaich spoke with Kimberly Smith, M.D., M.P.H., of ViiV Healthcare about 48-week data from the ARIA study announced at AIDS 2016. The results showed that a fixed-dose combination of dolutegravir/abacavir/lamivudine (Triumeq) was superior to a combination of atazanavir (Reyataz), ritonavir (Norvir) and tenofovir disproxil fumarate/emtricitabine (Truvada) in women who live with HIV. The better outcome in this open-label phase-3b study of 495 participants worldwide was mainly due to lower rates of discontinuation and virological failure in the dolutegravir/abacavir/lamivudine arm.

As people living with HIV become older, well-tolerated, effective antiretroviral regimens with fewer side effects that are easy to use become ever more important, according to Smith. To that end, her company is working on a two-drug combination of dolutegravir (Tivicay, DTG) and rilpivirine (Edurant). Enrollment in clinical trials for that medication has met internal goals of at least 20% of participants being female and at least a quarter being 50 years old or older. Other areas where dolutegravir could be helpful are among those who are coinfected with tuberculosis -- which is particularly relevant in Sub-Saharan Africa, as a second-line treatment and in pediatric HIV, Smith concluded.

Watch the video to learn more:

About the panelist:

  • Kimberly Y. Smith, M.D., M.P.H., ViiV Healthcare

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.